Merck Loosens 340B Contract Pharmacy Restrictions in Two States as Louisiana Law Takes Effect

Merck
Merck is the first drug manufacturer to announce it is issuing refunds to 340B providers in 2024.
Drug manufacturer Merck recently loosened its 340B program contract pharmacy restrictions in Louisiana and Arkansas just before Louisiana’s law protecting [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Senate Appropriators Urge HRSA to Penalize Drug Makers That Impose 340B Contract Pharmacy Conditions

Senate appropriations bill
The Democratic-controlled U.S. Senate Appropriations Committee urged HRSA to penalize drug manufacturers over 340B contract pharmacy restrictions.
Federal health care officials should use fines and “any available measures” to punish drug makers that deny 340B pricing for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Look to Specialty Pharmacy to Address 340B Challenges

Graphic image illustrating the revenue per dose that can be generated by a specialty contract pharmacy and an entity-owned specialty pharmacy for a leading rheumatoid arthritis medication.

SPONSORED CONTENT

Today’s U.S. health systems face significant financial challenges. Many are still trying to recoup pandemic-related losses stemming from forced shutdowns, elective procedure postponements, and reduced outpatient visits. These factors have contributed to billions in lost revenue, leaving many of

Read More »

Bipartisan AG Group Urges Senate to Protect 340B Contract Pharmacy Agreements, Require Provider Transparency

Connecticut Attorney General William Tong
Connecticut Attorney General William Tong (D) led a bipartisan group of state attorneys general urging changes to the 340B program.
Twenty-three state attorneys general urged a group of U.S. senators crafting a legislative overhaul of the 340B program to add [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges

JAMA 340B viewpoint
On the day a group of bipartisan Senators requested feedback from stakeholders, an influential academic and his colleagues published a series of recommendations to reform the 340B program in JAMA
A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Lee Harris, Principal, Sales and Strategic Relations, SUNRx

Lee Harris, SUNRx 340B Industry Leader
Lee Harris

Q: Where did you grow up?

I grew up in San Antonio and Victoria, TX and currently live in the Denver, CO area.

Q: Where did you go

Read More »

Louisiana’s New 340B Contract Pharmacy Law Goes Into Effect Today; PhRMA Sues and Teva Suspends its Restrictions in the State

PhRMA v. Landry
Brand drug trade group PhRMA is suing Louisiana over its law protecting 340B contract pharmacy arrangements.
Today is the first day of Louisiana’s new law protecting 340B program contract pharmacy arrangements and there have already been [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Claims Clearinghouse, Strengthening HRSA Among Few Consensus Areas in Responses to Senate 340B Overhaul Effort

Sen. John Thune
Sen. John Thune is part of a bipartisan group of six senators that solicited stakeholder advice on strategies to reform the 340B program.
The creation of a claims clearinghouse and increasing both the funding and authority of the federal agency overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

House E&C GOP Leaders’ Draft Bill Would Exempt Sterile Generic Injectables from 340B Pricing Requirements

House Energy & Commerce Committee's draft bill.
GOP leaders on the House Energy & Commerce Committee released a draft bill to address drug shortages that includes a provision that would exempt certain drug products from 340B pricing requirements.
Republican leaders of the U.S. House Energy and Commerce (E&C) Committee released a draft bill late last week that would [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA Tells Federal Court it Still Stands by its 340B Patient Definition in Closely Watched Case

Genesis
HRSA says it stands by its patient definition in Genesis' federal lawsuit seeking a far broader definition.
The U.S. Health Resources and Services Administration (HRSA) still stands by its 340B program patient definition, the agency said in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live